New Horizon seals high price for $263m HK IPO

biopharma_stocks_adobe_575x375.jpg
By Jonathan Breen
11 Feb 2021

New Horizon Health, a medical device manufacturer, has scooped up HK$2.04bn ($263.4m) from its IPO after strong institutional investor demand pushed pricing up to the top of the marketed range.

The Hangzhou-based company sold 76.59m primary shares at HK$26.66 each, according to a source familiar with the matter. The float, equal to 18.3% of its enlarged share capital, valued the firm at HK$11.1bn. The deal includes a greenshoe of 11.5m shares.

New Horizon’s eight-strong IPO syndicate, led by ...

Already a subscriber?

Continue reading this article

Try full access to GlobalCapital

Free trial